You are here : Home > The lab > Soluble VE-cadherin: A biomarker in metastatic and hormone-resistant breast cancer?

highlight / actuality

Soluble VE-cadherin: A biomarker in metastatic and hormone-resistant breast cancer?

After the discovery of a new bacterial virulence mechanism in Pseudomonas aeruginosa using a toxin called Exolysin, researchers from our laboratory show that type IV pili are necessary for ExlA to exert its cytotoxic activity by creating a close contact between the bacterium and the host cell.

Published on 27 June 2017
Breast cancer is the most common cancer in women and the leading cause of cancer death among European women. Metastatic breast cancer is generally considered as a heterogeneous disease for which the actual survival for individual patients varies widely, from just a few months to several years. Thus, stratification of patients into poor and good prognosis groups would lead to better personalised therapeutic approach. Therefore,there is a need of biomarkers to accurately predict outcome metastatic breast cancer patients.

Angiogenesis in breast cancer participates in tumor growth. Researchers from the laboratory have previously demonstrated [1] that structural modifications of VE-cadherin, a specific biomarker of endothelial cells, are involved in the control of vascular integrity. Thus, phosphorylation and cleavage of VE-cadherin are two processes involved in the destabilization of endothelial junctions.

The « SEMTOF » [2] study, promoted by the Léon Bérard Center, was designed to identify biological prognostic factors in patients with metastatic breast cancer resistant to hormone therapy. This study involved researchers from our laboratory for their expertise on VE-cadherin. The results of this study have shown that a high level of soluble VE-cadherin at the time of the diagnosis was correlated with a poor survival prognosis. Furthermore, a decreased level of so this biomarker after chemotherapy was associated with a good prognosis.

The potential value of soluble VE-cadherin as a survival biomarker for anti-angiogenic therapies is being studied by these two teams on the COMET cohort.
The COMET cohort is a prospective record of 500 patients with metastatic breast cancer treated with the combination of two molecules: paclitaxel and bevacizumab. #NCT01745757

Top page

Top page